← Back to Treatments
🏅 FDA Orphan Designation

Tarpeyo

budesonide delayed-release

Manufacturer: Calliditas Therapeutics

Indicated for:
IgA NephropathyOrphanProgressive dementia with neuroserpin inclusion bodiesOrphanImmunoglobulin A nephropathy

FDA-Approved Indications (3)

IgA NephropathyOrphan Designation

Indicated to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression.

to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) > or = 1.5 g/g

TARPEYO is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.

Population: adults

Indications & Usage

1 INDICATIONS AND USAGE TARPEYO is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. TARPEYO is a corticosteroid indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. ( 1 )

💙 Support Programs

View all →
Tarpeyo
Calliditas
Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.